论文部分内容阅读
目的探讨非小细胞肺癌(NSCLC)患者k-RAS基因突变与吉非替尼治疗晚期NSCLC患者疗效的相关性。方法回顾性分析我院接受吉非替尼治疗的88例NSCLC患者的组织标本,用聚合酶链式反应(PCR)扩增k-RAS基因第一和第二外显子后进行DNA测序,分析第12,13位密码子的突变情况与患者临床特征及疗效的相关性。结果 15例患者被检测出12,13密码子存在突变。88例接受吉非替尼治疗的患者中,4例完全缓解(CR),16例部分缓解(PR),客观有效率为22.7%(20/88)。k-RAS突变组客观缓解率显著低于k-RAS野生型组(P<0.05)。结论 k-RAS基因12/13密码子突变的NSCLC患者不能从吉非替尼治疗中获益。
Objective To investigate the relationship between k-RAS gene mutations and the efficacy of gefitinib in the treatment of advanced NSCLC in patients with non-small cell lung cancer (NSCLC). METHODS: Retrospective analysis of tissue samples from 88 NSCLC patients treated with gefitinib in our hospital was performed. Polymerase chain reaction (PCR) was used to amplify the first and second exons of k-RAS gene and DNA sequencing was performed. The mutations in codons 12 and 13 were associated with clinical characteristics and efficacy. Results There were mutations in the 12 and 13 codons detected in 15 patients. Of the 88 patients treated with gefitinib, 4 had complete remission (CR), 16 had partial remission (PR), and the objective and effective rate was 22.7% (20/88). The objective remission rate was significantly lower in the k-RAS mutation group than in the k-RAS wild type group (P<0.05). Conclusion Patients with NSCLC with a 12/13 codon mutation in k-RAS gene cannot benefit from gefitinib therapy.